neximmune.com (NEXI): Price-to-Projected Revenue Ratio

NEXI (NexImmune Inc) - company brandmark

NexImmune, Inc. (NEXI) targets demand from biopharmaceutical companies and patients within the cell immunotherapy segment. The trend in the expected P/S ratio reflects market expectations, where the metric determines this level. Growth scales via robotic bioreactors for culture control, while the operating model relies on outsourcing trials to external CROs under strict management supervision.

NEXI NexImmune Inc: Market Cap to Future Revenue Ratio in the range 07/04/2022 - 11/13/2026

Analytical breakdowns for NexImmune Corporation (NEXI)

- stock price and consensus target price:
Stock Quotes NexImmune|NEXI - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Value NexImmune Corporation|NEXI - Business Value
- book value of equity indicators:
Net Assets per Single Share NexImmune|NEXI - Total Stockholders' Equity|Market Cap to Net Assets Ratio neximmune.com|NEXI - Company Balance Sheet Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio NexImmune, Inc.|NEXI - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital NexImmune, Inc.|NEXI - Aggregate Debt Obligations|Debts to Book Capitalization NexImmune Corporation|NEXI - Long-Term Debt|Company Short-Term Debt NexImmune|Quick Ratio neximmune.com
- business earnings and investment ratios data:
NEXI - Net Profit|Expected Profit NexImmune, Inc.|NEXI - Market Cap to Net Income|Projected Price to Earnings NexImmune Corp|NEXI - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NexImmune Corporation|NEXI - Operating profit before amortization|Net earnings per share (EPS TTM) NexImmune|NEXI - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months neximmune.com|NEXI - Earnings per share growth this year|Earnings growth forecast for next year NexImmune, Inc.
- revenue and sales details:
NEXI - Company Gross Revenue|Company Projected Revenue NexImmune|NEXI - Market Cap to Revenue|Price-to-Projected Revenue Ratio NexImmune Corporation
Summary company analysis:NexImmune NEXI
Manufactured products of NexImmune Corporation

The development of innovative AIM drugs by NexImmune, Inc. (NEXI) requires significant investment, making revenue the key basis for valuation. By analyzing the expected P/S ratio, an investor can see the relationship between current market capitalization and projected sales, which allows them to filter out market noise and assess the extent to which the market consensus currently prices in the future success of clinical trials and partnerships into the current share price.

Competitor analysis

ImmunityBio - Forward Price-to-Revenue Multiple|Forward P/S Multiple Immunocore Holdings IMCR|JANX - Price-to-Projected Revenue Ratio|RCUS (Arcus Corp) - Market Cap to Projected Revenue|Zymeworks Inc. (ZYME) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio tangotx.com (TNGX)|Forward Price-to-Revenue Multiple IOVA|IMTX - Projected Price to Revenue|Forward Price-to-Revenue Multiple XNCR (Xencor Corp)|Price to Expected Revenue Ratio CMPX|Forward P/S Multiple REPL (Replimune Group, Inc.)|Forward Price to Sales LYEL|Innate Pharma - Forward P/S Multiple|Market Cap to Future Revenue Ratio Pyxis Oncology, Inc.|cgen.com (CGEN) - Price-to-Projected Revenue Ratio|IO Biotech Inc. - Forward Price to Sales|STRO (Sutro Biopharma, Inc.) - Forward P/S Multiple|Forward P/S Multiple minktherapeutics.com|Price-to-Projected Revenue Ratio Werewolf Therapeutics (HOWL)|IMMX: Future Price to Revenue|ALX Oncology Holdings - Forward Price-to-Revenue Multiple|cuebiopharma.com (CUE) - Market Cap to Future Revenue Ratio|PDSB - Price-to-Projected Revenue Ratio|SONN (Sonnet BioTherapeutics) - Market Cap to Projected Revenue|MAIA: Forward P/S Multiple|Market Cap to Future Revenue Ratio Liminatus Pharma Inc. (LIMN)|Forward Price-to-Revenue Multiple LVTX|Market Cap to Projected Revenue NXTC (NextCure Corporation)|Forward P/S Multiple LPTX|Market Cap to Expected Sales Ratio intensitytherapeutics.com|Price-to-Projected Revenue Ratio Sensei Biotherapeutics, Inc. SNSE|TOVX - Forward Price-to-Revenue Multiple|GRTS - Price-to-Projected Revenue Ratio|Kineta Corp (KA) - Forward Price-to-Revenue Multiple|TSBX (turnstonebio.com) - Forward Price-to-Revenue Multiple|vaccinex.com (VCNX) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Harpoon Therapeutics, Inc.